Time to Initial Appetite Suppression
Semaglutide starts suppressing appetite within hours of the first dose. In clinical studies, patients report reduced hunger as early as 1-2 hours post-injection, peaking around 4-6 hours due to its rapid activation of GLP-1 receptors in the brain's hunger centers.[1][2]
Onset with Weekly Dosing
With subcutaneous injections (Ozempic or Wegovy), appetite suppression begins on day 1 but strengthens over the first week. By days 3-7, most users notice consistent effects like smaller portion sizes and fewer cravings, as steady-state blood levels build.[3][4]
Full Steady-State Effects
Maximum appetite suppression occurs after 4-5 weeks of weekly dosing at maintenance levels (e.g., 1-2.4 mg). Trials show 20-30% greater reductions in daily calorie intake by week 4 compared to week 1, with effects plateauing around week 8.[1][5]
Factors Affecting Speed
- Dose: Higher starting doses (0.25 mg ramps to 2.4 mg) accelerate onset; oral Rybelsus (3-14 mg daily) acts within 1 hour but builds slower overall.[2][6]
- Individual variation: Faster in those with higher BMI or insulin resistance; slower if taken with food or in low-GLP-1 responders.[4]
- Tolerance: Effects may wane slightly after 6-12 months in 10-20% of users, per long-term data.[7]
Clinical Evidence from Trials
STEP trials (Wegovy) measured appetite via validated scales: 15-25% hunger score drop by week 4, correlating with 5-10% weight loss.[1][5] SUSTAIN trials (Ozempic) confirm similar timelines for type 2 diabetes patients.[3]
What If It Doesn't Work Quickly?
If no appetite change by week 2, check injection technique, dose escalation, or consult a doctor—rare GI side effects can mask early signals. Not everyone responds identically; 5-10% see minimal effects.[4][7]
[1]: NEJM, STEP 1 Trial (2021) - https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[2]: Novo Nordisk Prescribing Info (Ozempic) - https://www.novo-pi.com/ozempic.pdf
[3]: Diabetes Care, SUSTAIN Trials Meta-Analysis (2018) - https://diabetesjournals.org/care/article/41/9/1966/36377
[4]: Lancet, Semaglutide Pharmacokinetics Review (2022) - https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00045-7/fulltext
[5]: NEJM, STEP 4 Extension (2022) - https://www.nejm.org/doi/full/10.1056/NEJMoa2114833
[6]: FDA Label (Rybelsus) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
[7]: JAMA, Long-Term Weight Regain Analysis (2023) - https://jamanetwork.com/journals/jama/fullarticle/2804054